Overcoming kinase resistance in chronic myeloid leukemia

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib is a BCR-ABL tyrosine kinase inhibitor effective for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
• Development of resistance to imatinib, both BCR-ABL dependent (mutations, amplification) and independent (efflux pumps, alternative pathways like SRC kinases), limits its long-term efficacy.
• Understanding resistance mechanisms is crucial for developing alternative and improved therapeutic strategies.

Purpose of the Study:

• To review the mechanisms of imatinib resistance in CML and Ph+ ALL.
• To highlight the role of dasatinib as a treatment option for patients resistant or intolerant to imatinib.
• To discuss future directions in CML and Ph+ ALL therapy, including combination approaches.

Main Methods:

• Literature review of studies on imatinib resistance mechanisms.
• Analysis of dasatinib's efficacy, binding characteristics, and kinase targets.
• Evaluation of emerging therapeutic strategies for resistant CML and Ph+ ALL.

Main Results:

• BCR-ABL mutations and gene amplification are key drivers of imatinib resistance.
• BCR-ABL-independent resistance involves multidrug resistance proteins and SRC family kinases (LYN, HCK).
• Dasatinib demonstrates superior binding potency, inhibits both active and inactive BCR-ABL conformations, and targets SRC kinases, showing high activity in imatinib-resistant/intolerant CML and Ph+ ALL, except for the T315I mutation.

Conclusions:

• Imatinib resistance necessitates alternative treatment options.
• Dasatinib is a highly effective agent for managing imatinib-resistant/intolerant CML and Ph+ ALL.
• Future therapies may involve combination treatments to overcome resistance, including targeting specific mutations like T315I.